CONMED Corp (CNMD) · Oct 28, 2026 · Earnings
Beat — Adjusted EPS $1.04 vs ~$1.00 consensus
CONMED earnings beat on adjusted EPS and delivered sharp margin expansion, but revenue missed slightly and full-year organic growth guidance narrowed.
CONMED is in the middle of a portfolio reset: it is exiting gastroenterology products and concentrating resources on minimally invasive surgery, smoke evacuation, and orthopedic soft-tissue repair, led by AirSeal, Buffalo Filter, and BioBrace.
The quarter beat on the metric that matters most for earnings. Adjusted diluted EPS was $1.04 versus a published consensus of approximately $1.00, while revenue of $335.6 million was slightly below the roughly $336.3 million expectation. Management explicitly said adjusted EPS exceeded expectations. 〔0〕
| Metric | Q3 2026 | Q3 2025 / prior guidance | Read |
|---|---|---|---|
| Revenue | $335.6M | $337.9M | Down 0.7% reported (Consolidated Condensed Statements of Income) |
| Organic constant-currency sales growth | 6.7% | — | Strong underlying growth despite GI exits (Sales Summary) |
| Adjusted diluted EPS | $1.04 | $1.08 | Above ~$1.00 consensus; below prior-year adjusted EPS (Reconciliation of Reported Net Income to Adjusted Net Income) |
| Adjusted EBITDA margin | 20.2% | 19.4% | Up 80 basis points (Reconciliation of Net Income to EBITDA & Adjusted EBITDA) |
| FY2026 adjusted EPS guidance | $4.54–$4.61 | $4.48–$4.60 | Raised at both ends (Updated Financial Guidance) |
| FY2026 organic constant-currency sales growth | 5.0%–5.5% | 5.0%–6.0% | High end reduced (Updated Financial Guidance) |
Underlying demand was much better than reported revenue suggests. Total sales declined 0.7% because the company is removing exited GI products from its portfolio, but organic constant-currency growth reached 6.7% in the quarter. Orthopedic Surgery grew 12.7% organically in constant currency and General Surgery grew 12.6%, showing that the focused portfolio is gaining traction rather than simply shrinking. (Sales Summary — Three Months Ended September 30, 2026)
Profitability was the strongest part of the release. Reported operating margin rose to 11.1% from 3.5%, while adjusted EBITDA margin improved to 20.2% from 19.4%. That expansion reflects better operating leverage and a cleaner portfolio, although the quarter still included $3.2 million of operational optimization costs and $1.9 million tied to European medical-device regulations. (Consolidated Condensed Statements of Income; Reconciliation of Net Income to EBITDA & Adjusted EBITDA)
The guidance change is favorable on earnings but less encouraging on growth. CONMED raised the full-year adjusted EPS range from $4.48–$4.60 to $4.54–$4.61, but narrowed the organic constant-currency sales outlook from 5.0%–6.0% to 5.0%–5.5%. The company is converting solid underlying demand into better earnings, but the top-line ceiling is lower than it previously expected. 〔1〕
Bottom line: This was a narrow earnings beat built on margin improvement and healthy growth in the prioritized businesses, not a clean revenue win. The portfolio reset is working operationally, but the reduced sales-growth ceiling keeps the overall read from being decisively strong.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!